[go: up one dir, main page]

ES2191977T3 - Soluciones y dispersiones en estado solido de farmacos poco solubles en agua. - Google Patents

Soluciones y dispersiones en estado solido de farmacos poco solubles en agua.

Info

Publication number
ES2191977T3
ES2191977T3 ES98955458T ES98955458T ES2191977T3 ES 2191977 T3 ES2191977 T3 ES 2191977T3 ES 98955458 T ES98955458 T ES 98955458T ES 98955458 T ES98955458 T ES 98955458T ES 2191977 T3 ES2191977 T3 ES 2191977T3
Authority
ES
Spain
Prior art keywords
water
pharmacos
solubles
dispersions
little
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98955458T
Other languages
English (en)
Inventor
Siva Narayan Tallavajhala
Xiuying Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Application granted granted Critical
Publication of ES2191977T3 publication Critical patent/ES2191977T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención describe una composición útil como excipiente farmacéutico, el procedimiento de producción del mismo y las composiciones farmacéuticas producidas de esta manera. En particular, la invención se aplica para mejorar la solubilidad de los compuestos terapéuticamente activos ligeramente solubles en agua, por medio de un excipiente que comprende una mezcla de : (a) glicéridos poliglicolizados saturados y (b) copolímeros secuenciados polioxipropileno - polioxietileno, en la que se mejora la solubilidad del compuesto terapéuticamente activo poco soluble en la composición farmacéutica.
ES98955458T 1997-10-27 1998-10-15 Soluciones y dispersiones en estado solido de farmacos poco solubles en agua. Expired - Lifetime ES2191977T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6333897P 1997-10-27 1997-10-27

Publications (1)

Publication Number Publication Date
ES2191977T3 true ES2191977T3 (es) 2003-09-16

Family

ID=22048528

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98955458T Expired - Lifetime ES2191977T3 (es) 1997-10-27 1998-10-15 Soluciones y dispersiones en estado solido de farmacos poco solubles en agua.

Country Status (10)

Country Link
EP (1) EP0996429B1 (es)
JP (1) JP2001520984A (es)
CN (1) CN1190187C (es)
AT (1) ATE232087T1 (es)
DE (1) DE69811233T2 (es)
DK (1) DK0996429T3 (es)
ES (1) ES2191977T3 (es)
NO (1) NO329755B1 (es)
PT (1) PT996429E (es)
WO (1) WO1999021534A1 (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2775597B1 (fr) * 1998-03-04 2001-04-20 Gattefosse Ets Sa Pellet administrable par voie orale apte a ameliorer la biodisponibilite de la substance active, procede de fabrication
AU771960B2 (en) * 1998-06-05 2004-04-08 Forbes Medi-Tech Inc. Compositions comprising phytosterol and/or phytostanol having enhanced solubility and dispersability
US20030166525A1 (en) 1998-07-23 2003-09-04 Hoffmann James Arthur FSH Formulation
SE9901667D0 (sv) * 1999-05-07 1999-05-07 Astra Ab Method and device for forming particles
SE9902742D0 (sv) * 1999-07-20 1999-07-20 Astra Ab New pharmaceutical formultion
US20010036479A1 (en) * 2000-01-14 2001-11-01 Gillian Cave Glyburide composition
ITMI20011337A1 (it) * 2001-06-26 2002-12-26 Farmatron Ltd Composizioni farmaceutiche orali a rilascio modificato del principio attivo
ITMI20011338A1 (it) * 2001-06-26 2002-12-26 Farmatron Ltd Composizioni farmaceutiche orali a rilascio immediato del principio attivo
RU2330642C2 (ru) * 2001-07-06 2008-08-10 Лайфсайкл Фарма А/С Регулируемая агломерация
IS6633A (is) * 2002-11-22 2004-05-23 Omega Farma Ehf. Samsetningar af fínasteríð töflum
BR0215979A (pt) * 2002-12-13 2005-11-01 Jagotec Ag Formulação de espironolactona nanoparticulada tópica, uso de nanossuspensões de espironolactona, sistema de rede cristalina, e, processo para a preparação de uma formulação de espironolactona nanoparticulada tópica
US20040162333A1 (en) * 2003-02-19 2004-08-19 Naima Mezaache Rapid absorption selective 5-HT agonist formulations
PL1610822T5 (pl) 2003-04-02 2019-05-31 Ares Trading Sa Płynne formulacje farmaceutyczne FSH i LH z niejonowym surfaktantem
AU2004248931B2 (en) 2003-06-20 2009-07-16 Ares Trading S.A. Freeze-dried FSH / LH formulations
JP2007511518A (ja) * 2003-11-13 2007-05-10 アルザ・コーポレーシヨン 溶融ブレンド分散体
CA2548376A1 (en) 2003-12-31 2005-07-21 Pfizer Products Inc. Solid compositions of low-solubility drugs and poloxamers
TW200616681A (en) * 2004-10-05 2006-06-01 Recordati Ireland Ltd Lercanidipine capsules
WO2006053882A2 (en) * 2004-11-17 2006-05-26 Ares Trading S.A. Benzothiazole formulations and use thereof
EP1690528A1 (de) * 2005-02-11 2006-08-16 Abbott GmbH & Co. KG Herstellung von Dosierungsformen mit einer festen Dispersion eines mikrokristallinen Wirkstoffs
ES2277767B1 (es) * 2005-11-04 2008-04-01 Simbec Iberica, S.L. Formas orales solidas de ebastina.
PT1962808E (pt) * 2005-12-14 2010-10-29 Hoffmann La Roche Formulação de precursor de fármaco para o hcv
ATE503484T1 (de) * 2006-08-16 2011-04-15 Novartis Ag Verfahren zur herstellung fester dispersionen von midostaurin
EP1972336A1 (en) * 2007-03-19 2008-09-24 LEK Pharmaceuticals D.D. Hot-melt micropellets
WO2010143199A1 (en) * 2009-06-11 2010-12-16 Suven Nishtaa Pharma Private Limited Solid lipid dispersion for aqueous solubility enhancement of poorly water soluble drugs
EP2510924B1 (en) * 2009-12-08 2014-10-08 IL Hwa Co., Ltd SOLID DISPERSIONS CONTAINING 20-O-ß-D-GLUCOPYRANOSYL-20(S)-PROTOPANAXADIOL
US9504664B2 (en) 2010-10-29 2016-11-29 Infirst Healthcare Limited Compositions and methods for treating severe pain
US9271950B2 (en) 2010-10-29 2016-03-01 Infirst Healthcare Limited Compositions for treating chronic inflammation and inflammatory diseases
US9744132B2 (en) 2010-10-29 2017-08-29 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US10695432B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US11224659B2 (en) 2010-10-29 2022-01-18 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US11202831B2 (en) 2010-10-29 2021-12-21 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US9308213B2 (en) 2010-10-29 2016-04-12 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US8895536B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating chronic inflammation and inflammatory diseases
US10695431B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US11730709B2 (en) 2010-10-29 2023-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
PT2635307T (pt) * 2010-11-01 2020-11-03 Melinta Subsidiary Corp Composições farmacêuticas
EP2455068A1 (en) * 2010-11-09 2012-05-23 F. Hoffmann-La Roche AG Pharmaceutical composition for treating HCV infections
US20130316006A1 (en) * 2012-05-03 2013-11-28 Kala Pharmaceuticals, Inc. Particles, compositions and methods for ophthalmic and/or other applications
DE102012105512A1 (de) * 2012-06-25 2014-04-24 Hennig Arzneimittel Gmbh & Co. Kg Arzneiform zur verlängerten Freisetzung von Wirkstoffen
US10994013B2 (en) 2013-04-24 2021-05-04 Temple University—Of the Commonwealth System of Higher Education Solid dosage form containing arabinogalactan
WO2015013772A1 (en) * 2013-08-01 2015-02-05 Monash University Compositions and preparation methods of low melting ionic salts of poorly- water soluble drugs
ES2863500T3 (es) 2015-04-10 2021-10-11 Capsugel Belgium Nv Formulaciones lipídicas de acetato de abiraterona
EP3492070A1 (en) * 2017-11-30 2019-06-05 BIT Pharma GmbH Process and device for preparing a solid dispersion
US12343430B2 (en) 2019-04-08 2025-07-01 Mudanjiang Linrun Pharama Excipients Llc. Methods of improving pharmaceutical substance solubilization and products thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8524421D0 (en) * 1985-10-03 1985-11-06 Boots Co Plc Therapeutic agents
JPS62120315A (ja) * 1985-11-20 1987-06-01 Shin Etsu Chem Co Ltd 経口投与型徐放性錠剤の製造方法
JPH05255125A (ja) * 1992-02-29 1993-10-05 Upjohn Co:The 徐放性製剤およびその製法
JPH06316517A (ja) * 1993-02-22 1994-11-15 Grelan Pharmaceut Co Ltd 放出制御製剤
US5487887A (en) * 1993-10-28 1996-01-30 Bristol-Myers Squibb Company Clear antiperspirant roll-on compositions
US5545628A (en) * 1995-01-10 1996-08-13 Galephar P.R. Inc. Pharmaceutical composition containing fenofibrate
JPH08268878A (ja) * 1995-03-06 1996-10-15 Yoshiyuki Masui 経口医薬品並びに加工食品
US5883103A (en) * 1995-06-07 1999-03-16 Shire Laboratories Inc. Oral acyclovir delivery
FR2761265B1 (fr) * 1997-03-28 1999-07-02 Sanofi Sa Composition pharmaceutique pour l'administration orale d'un derive du n-piperidino-3-pyrazolecarboxamide, de ses sels et de leurs solvates

Also Published As

Publication number Publication date
PT996429E (pt) 2003-06-30
EP0996429B1 (en) 2003-02-05
EP0996429A1 (en) 2000-05-03
NO20002133D0 (no) 2000-04-26
DE69811233D1 (de) 2003-03-13
CN1278164A (zh) 2000-12-27
NO20002133L (no) 2000-04-26
ATE232087T1 (de) 2003-02-15
NO329755B1 (no) 2010-12-13
DE69811233T2 (de) 2003-11-20
DK0996429T3 (da) 2003-05-26
CN1190187C (zh) 2005-02-23
JP2001520984A (ja) 2001-11-06
WO1999021534A1 (en) 1999-05-06

Similar Documents

Publication Publication Date Title
ES2191977T3 (es) Soluciones y dispersiones en estado solido de farmacos poco solubles en agua.
UY26977A1 (es) Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti-inflamatorios y analgésicos
GT200000219A (es) Composiciones farmaceuticas que proporcionan concentraciones potenciadas de farmaco.
DE60142891D1 (de) Azetidinderivate enthaltende pharmazeutische zusammensetzungen, die azetidinderivate und deren herstellung
JOP20210301A1 (ar) بيرولات ثلاثية الحلقة مكثفة كمُعدِّلات مضاد تريبسين ألفا-1
AR028833A1 (es) Compuestos inhibidores de metaloproteasas, composiciones farmaceuticas, uso para la manufactura de medicamentos, metodo de tratamiento y procedimiento para su preparacion
AR030609A1 (es) Composicion catartica
CO5680109A1 (es) Compuestos para el tratamiento de la disfuncion sexual femenina
AR024159A1 (es) Nuevo uso de compuestos como agentes antibacterianos
PA8591701A1 (es) Derivados de pirrolopirimidina
BR0114799A (pt) Compostos de ácido cianofenoxi carboxìlico e composições para liberar agentes ativos
UY27368A1 (es) Nuevos compuestos
SE0200979D0 (sv) New compounds
UY27320A1 (es) Nuevas composiciones farmacéuticas
BR0207872A (pt) Composto para liberar agentes ativos, composição, forma de unidade de dosagem e método de administração
AR033288A1 (es) Metodo para fabricar una composicion farmaceutica de dosis baja que tiene una distribucion y potencia del farmaco uniformes
UY27886A1 (es) Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco.
ES2188426B1 (es) Composicion farmaceutica para el tratamiento de la psoriasis y otras dermopatias.
DK1109560T3 (da) Som AICARFT-inhibitorer anvendelige forbindelser
DK1638582T3 (da) Anvendelse af hyaluronsyre til fremstilling af kompositioner til behandling af tilbagevendende after
AR001769A1 (es) Benzamida enterocinética composiciones farmacéuticas que las contienen procedimiento para la preparación de dichas composiciones farmacéuticas el uso de dichos compuestos para la manufactura de medicamentos y un procedimiento para su preparación
PA8525801A1 (es) Compuestos de pirazol, composiciones farmacéuticas, y métodos para modular y/o inhibir la actividad de erab/hadh2
ATE308540T1 (de) Antithrombosemittel
AR035064A1 (es) 3-(1-metil-3-indolil)-4-(1-metil-6-nitro-3-indolil)-1h-pirrol-2,5-diona, en forma amorfa, procesos para prepararla, composicion farmaceutica que la comprende y uso de dicho compuesto en la fabricacion de medicamentos
BR0008739A (pt) Composições de liberação controlada debeta-histina